Phase III Study of OT202 in Treating Moderate to Severe Dry Eye

NCT07740564 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

842

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye

Interventions

DRUG: OT202 conc 1%
DRUG: Placebo

Sponsor

Ocumension Therapeutics (Suzhou) Co., Ltd